| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2023-080 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 股东股份解除质押的公告 | 剩余被质押股份数量占其所持股份比例 | 0% | | --- | --- | | 剩余被质押股份数量占公司总股本比例 | 0% | 本次解除质押的股份计划用于后续质押，公司将依据相关规定及时履行信息 披露义务。 二、股东及其一致行动人累计质押股份情况 截至本公告披露日，股东刘辉先生及其一致行动人朱文怡女士所持公司股份 均为无限售条件流通股，累计质押股份情况见下表： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次股份被解质情况 上海润达医疗科技股份有限公司（以下简称"公司"）于 2023 年 9 月 14 日接到股东刘辉先生通知，获悉其原质押给中信建投证券股份有限公司的股份解 除质押，具体如下： | 股东名称 | 刘辉 | | --- | ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2023-079 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2022 年度股东大会审议通过：自 2023 年 5 月 19 日至 2023 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 402,600 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：三家全资子公司：杭州润达、青岛益信、惠中医疗；五 家控股子公司：合肥润达、润达榕嘉、合肥三立、武汉优科联盛、云南 康泰。被担保 ...

Guarantees and Debt - Total guarantees provided by the company to subsidiaries amounted to ¥1,386,962,483.49 during the reporting period[6]. - The total guarantee balance for subsidiaries at the end of the reporting period was ¥2,701,015,347.18, representing 69.46% of the company's net assets[6]. - The company provided debt guarantees exceeding 70% asset-liability ratio for certain entities amounting to ¥1,298,728,969.47[6]. - The total amount of guarantees exceeding 50% of net assets was ¥756,808,362.96[6]. - The total amount of guarantees (including those to subsidiaries) was ¥2,701,015,347.18[6]. - The company reported no significant changes in the credit status of its guarantors during the reporting period[21]. Convertible Bonds - The number of convertible bond holders at the end of the reporting period was 6,932[21]. - The total amount of convertible bonds not yet converted was ¥548,696,000, representing 99.7629% of the total issued convertible bonds[23]. - The cumulative number of shares converted from convertible bonds was 98,338, accounting for 0.0170% of the total shares before conversion[23]. - The adjusted conversion price for the convertible bonds as of July 18, 2023, was ¥13.10[23]. Financial Performance - Total operating revenue for the first half of 2023 was ¥4,521,325,952.24, a decrease of 5.02% compared to ¥4,760,967,576.37 in the same period of 2022[30]. - Total operating costs decreased to ¥4,217,930,198.11 from ¥4,421,120,726.23, reflecting a reduction of 4.6%[30]. - Net profit for the first half of 2023 was ¥261,323,734.69, down from ¥275,080,465.06, representing a decline of 5.0%[31]. - Research and development expenses increased to ¥65,941,195.98, up from ¥58,954,312.14, indicating a growth of 11.8%[30]. - Investment income rose to ¥68,096,217.37 from ¥62,885,407.24, marking an increase of 8.5%[31]. - The company reported a decrease in inventory from ¥1,615,932,474.38 to ¥1,417,773,776.42, a reduction of 12.2%[30]. - Cash and cash equivalents increased to ¥1,131,737,727.60 from ¥1,007,052,275.15, reflecting a growth of 12.3%[30]. - The company’s total assets as of June 30, 2023, amounted to ¥10,089,639,469.08, compared to ¥9,819,157,524.87 at the end of 2022, an increase of 2.75%[30]. - The company’s financial expenses increased to ¥156,723,776.52 from ¥150,534,212.35, a rise of 4.6%[30]. - The company’s tax expenses rose to ¥86,615,817.19 from ¥64,386,249.90, an increase of 34.6%[31]. Cash Flow - The net cash flow from operating activities for the first half of 2023 was ¥240,373,516.33, a significant improvement from a negative ¥100,324,225.83 in the same period of 2022[36]. - Total cash inflow from investment activities increased to ¥263,172,371.95 in the first half of 2023, compared to ¥195,581,722.51 in the previous year[36]. - Cash outflow from investment activities rose to ¥342,976,265.53, up from ¥181,214,378.82 in the first half of 2022, resulting in a net cash flow of -¥79,803,893.58[36]. - Cash inflow from financing activities reached ¥3,040,326,535.68, significantly higher than ¥1,901,970,615.52 in the same period last year[36]. Equity and Ratios - The company reported a net profit of ¥156,840,561.06 for the first half of 2023, reflecting a 6.37% increase from ¥147,454,226.39 in the previous year[46]. - The current ratio improved to 1.22, up from 1.15 at the end of the previous year, indicating better short-term financial health[46]. - The debt-to-asset ratio slightly decreased to 65.30% from 65.49%, showing a marginal improvement in leverage[46]. - The cash interest coverage ratio increased significantly to 1.99, compared to -0.44 in the same period last year, indicating improved cash flow management[46]. - The company’s total equity at the end of the reporting period was ¥5,009,850,314.82, reflecting a slight increase from the previous year[38]. - The company maintained a loan repayment rate of 100%, indicating strong financial discipline in managing debt obligations[46]. Accounts Receivable and Provisions - The total accounts receivable balance at the end of the period is CNY 292,079,427.38, an increase from CNY 244,563,082.28 at the beginning of the period[53][56]. - The provision for bad debts increased to CNY 2,062,621.03 from CNY 1,876,647.24, reflecting a significant adjustment in credit loss expectations[54][52]. - The accounts receivable aging report shows that CNY 146,063,561.41 is due within one year, while CNY 83,275,906.09 is due between one to two years[53]. - The company recorded a provision for credit losses of CNY 185,973.79 during the reporting period[52]. - The total bad debt provision as of June 30, 2023, is RMB 15,286,559.23, an increase from RMB 14,180,907.74 at the beginning of the year, reflecting a provision of RMB 1,101,622.45 during the period[194]. - The company recorded a new provision for bad debts of RMB 1,101,622.45, with specific contributions of RMB 308,997.84, RMB 623,661.78, and RMB 168,962.83 across different stages[194]. Prepayments and Inventory - The total prepayments at the end of the period amounted to ¥992,899,753.06, with 83.68% due within one year[87]. - The prepayments due within one year increased from ¥728,437,064.51 (90.00%) at the beginning of the period[87]. - Prepayments due between one to two years were ¥135,168,303.46, representing 13.61% of the total[87]. - The company reported a decrease in prepayments due between two to three years from ¥17,094,955.30 (2.11%) to ¥14,752,626.51 (1.49%)[87]. - The company has a total inventory balance as of June 30, 2023, of RMB 1,427,943,641.63, down from RMB 1,626,596,434.47 at the beginning of the year[196]. - The provision for inventory impairment is RMB 10,169,865.21, reflecting a decrease in the value of inventory[197]. Revenue Recognition - The company recognizes revenue when control of the goods is transferred to the customer, which includes conditions such as contract approval and clear payment terms[200]. - Revenue is allocated to each performance obligation based on the relative standalone selling prices of the promised goods[200]. - If certain conditions are met, revenue is recognized over time based on the progress of the performance obligation[200]. - The company does not recognize fair value changes of equity instruments[199]. - The company recognizes revenue based on incurred costs when the progress of the performance obligation cannot be reasonably determined[200]. Strategic Plans and Market Position - The company reported a significant increase in revenue, achieving a total of 1.2 billion in Q2 2023, representing a 15% year-over-year growth[117]. - User data showed an increase in active users, reaching 5 million, which is a 20% increase compared to the previous quarter[117]. - The company provided guidance for Q3 2023, expecting revenue to be between 1.3 billion and 1.4 billion, indicating a growth rate of 10% to 15%[117]. - New product launches included a state-of-the-art medical device, projected to generate an additional 200 million in revenue over the next year[117]. - The company is investing in R&D, allocating 10% of its revenue towards developing new technologies and improving existing products[117]. - Market expansion plans include entering two new international markets by the end of 2023, aiming for a 5% market share in each[117]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential mergers and acquisitions[117]. - The company reported a decrease in operating expenses by 8%, improving overall profitability margins[117]. - The company emphasized its commitment to sustainability, with plans to reduce carbon emissions by 25% by 2025[117]. - The company is implementing a new customer loyalty program expected to increase customer retention rates by 15% over the next year[117].

本次会议审议并通过如下议案： （一）审议通过了《关于审议公司2023年半年度报告及摘要的议案》。 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2023-074 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届董事会第七次会 议通知于2023年8月18日以邮件形式发出，会议于2023年8月28日（星期一） 13:00-15:00在上海市虹口区乍浦路89号星荟中心1座8楼公司会议室以现场方式 召开。会议应到董事11人，实到董事11人，公司监事严晨、吴伟钟、丁秋泉和高 级管理人员廖上林列席了会议。会议由公司董事长张诚栩先生主持。 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议 ...

一、关于增加 2023 年度日常关联交易预计的议案 公司与关联人的关联交易，与公司日常生产经营和企业发展密切相关，保障 了公司生产经营活动的正常开展，有利于公司经营，符合公司经营发展战略。关 联交易价格按照市场价格执行，公平合理；亦不会影响公司的独立性；公司董事 会在审议该关联交易议案时，表决程序合法，关联董事进行了回避，符合有关法 律、法规和公司章程的规定。我们同意上述议案。 独立董事：王晶晶、何嘉、CHAN HWANG TONG、冯国富 2023 年 8 月 28 日 上海润达医疗科技股份有限公司 独立董事关于公司第五届董事会第七次会议 相关事项的独立意见 根据《上市公司独立董事规则》、《上海证券交易所股票上市规则》和《公 司章程》等的有关规定，我们作为上海润达医疗科技股份有限公司（以下简称"公 司"）的独立董事，对公司第五届董事会第七次会议的相关议案进行了审议，基于 我们的独立判断，经认真研究，现就该次会议所涉及的相关事项发表独立意见如 下： ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2023-077 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 2023上半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金的数额、资金到位情况 根据公司2019年2月27日召开的第三届董事会第二十六次会议及公司2019 年 3 月 18 日召开的 2019 年第一次临时股东大会决议，并经中国证券监督管理委 员会"证监许可[2020]586 号"《关于核准上海润达医疗科技股份有限公司公开发 行可转换公司债券的批复》核准，上海润达医疗科技股份有限公司（以下简称"公 司"）向社会公开发行可转换为公司 A 股股票的可转换公司债券，债券票面金额 为人民币 100.00 元，按票面金额发行，发行数量 5,500,000 张，期限 6 年，募集 资金总额 550,000,000.00 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2023-076 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于增加 2023 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因业务发展需要及新增关联方，公司依据实际情况，增加与部分关联方 2023年度日常关联交易预计的金额。 本次日常关联交易不会导致公司对关联方形成依赖，不会影响上市公司 的独立性。 本次增加的日常关联交易金额在公司董事会审批范围之内，无需提交股 东大会审议。 一、增加日常关联交易履行的审议程序 2023 年 4 月 24 日公司第五届董事会第四次会议以 8 票同意、0 票弃权、0 票反对的审议结果审议通过了《关于公司 2023 年度日常关联交易预计的议案》。 关联董事刘辉先生、胡震宁先生、陆晓艳女士已回避表决。 2023年5月19日，公司2022年年度股东大会会议审议通过了《关于公司 ...

根据《上海证券交易所股票上市规则》、《上市公司独立董事规则》和《上海 润达医疗科技股份有限公司章程》等有关规定，我们作为上海润达医疗科技股份 有限公司（以下简称"公司"）的独立董事，我们预先对公司第五届董事会第七次 会议资料进行了审阅，现发表如下事前认可意见： 一、关于增加 2023 年度日常关联交易预计的议案 上海润达医疗科技股份有限公司 独立董事关于公司第五届董事会第七次会议 相关事项的事前认可意见 该等关联交易，是为了保障公司生产经营活动的正常开展，符合公司经营发 展战略，有利于公司经营。该关联交易价格按照市场价格执行，符合市场定价原 则，公平合理；不存在损害上市公司及全体股东利益的情形，特别是非关联股东 和中小股东利益的情形，亦不会影响公司的独立性。我们同意将上述议案提交董 事会审议，关联董事应当回避表决。 独立董事：王晶晶、何嘉、CHAN HWANG TONG、冯国富 2023 年 8 月 28 日 ...

上海润达医疗科技股份有限公司 监事会决议公告 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2023-075 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届监事会第六次 会议通知于 2023 年 8 月 18 日以邮件形式发出，会议于 2023 年 8 月 28 日（星期 一）15:00-17:00 在上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼公司会议室以现 场方式召开。会议应到监事 3 人，实到监事 3 人，公司董事会秘书张诚栩先生出 席了会议，会议由公司监事会主席严晨女士主持。 本次监事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议合 法有效。 二、监事会会议审议情况 公司监事会认为：公司编制的《2023 上 ...

上海润达医疗科技股份有限公司 董事会审计委员会审核意见 根据《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管 指引第 5 号——交易与关联交易》及《上海润达医疗科技股份有限公司章程》等 文件的有关规定，上海润达医疗科技股份有限公司（下称"公司"）董事会审计 委员会全面审查了公司提交的第五届董事会第七次会议的相关议案，并发表如下 意见： 一、关于增加 2023 年度日常关联交易预计的议案 董事会审计委员会 2023 年 8 月 28 日 该等日常关联交易是公司持续经营和日常管理中必要的日常业务往来，同时 也有利于公司降低经营成本，并获得便利、优质、稳定的服务；公司与关联方交 易时按照公允原则，不存在损害公司及其他股东特别是中小股东和非关联股东的 利益的情形，不会对公司以及公司未来财务状况、经营成果产生重大影响；关联 交易对公司独立性没有影响，公司不会因此类交易而对关联方形成主要依赖。我 们同意上述事项。 上海润达医疗科技股份有限公司 ...